Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.
포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.
터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May...
Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis PR...
Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at...
Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update PR Newswire VICTORIA, BC, May 8, 2024...
Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board PR Newswire VICTORIA, BC, May 2, 2024 --Advisory Board to Provide...
Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024 PR...
Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference PR Newswire VICTORIA, BC, April 8, 2024 VICTORIA...
Eupraxia Pharmaceuticals Begins Trading on Nasdaq Today PR Newswire VICTORIA, BC, April 5, 2024 VICTORIA, BC, April 5, 2024 /PRNewswire/...
Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024 PR Newswire VICTORIA, BC, April 3, 2024 Company's Listing Application...
Eupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial Results PR Newswire VICTORIA, BC, April 1, 2024 VICTORIA, BC, April 1, 2024...
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES VICTORIA, British Columbia, March...
Eupraxia Pharmaceuticals Reports Positive Topline Data in its Phase 2b Osteoarthritis Trial with EP-104IAR PR Newswire VICTORIA, BC, June 26...
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES VICTORIA, British Columbia, April...
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관